Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma
Published January 24, 2023
Views 123 | Likes 1 | Comments 0
At a glance
Views
123
Likes
1
Comments
0
Performance vs. channel
Outlier score
Engagement rate
More features coming
We're working on new analytics and tools. Stay tuned.
About
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, briefly comments on the results of a Phase I study evaluating ABBV-383, a BCMA × CD3 bispecific antibody in patients with relapsed/refractory (R/R) multiple myeloma (NCT03933735). Prof. Vij explains that this agent eliminates the need for step-up d…
- Published
- January 24, 2023
- Made for kids
- No
More features coming
We're working on new analytics and tools. Stay tuned.